Orphan Drugs Market is expected to reach US$ 355.12 Bn. by 2029, at a CAGR of 10.83% during the forecast period. The report focuses on the orphan drugs market value at the top regions and countries of the world, which shows a regional development, including market size, share, revenue, and much more across the globe. The report has covered, capacity, production value, cost/profit, and supply/demand by statistical analysis. A brief analysis of drivers, restraints, opportunities, and challenges in the market is also covered with examples by region. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. It also has covered the analysis of key player’s growth strategies, micro and macro analysis of markets, key developments, and key trends in the market.To know about the Research Methodology :- Request Free Sample Report
Orphan Drugs Market Dynamics:
An orphan drug is used for the treatment of rare disorders. The patients suffering from rare disorders are less, and hence pharmaceutical industries do not interest in the manufacturing of drugs for the same. To deliver proper treatment for rare diseases and to motivate pharmaceutical and biotechnology companies to participate in treatment for rare diseases, governments have shaped several legal and financial incentives. The factors such as the rising occurrence of rare diseases and growing investment in R&D are expected to drive the growth of the orphan drug market. Also, the rising cases of neurological disorders will positively impact the healthy growth of the orphan drug market. The growing healthcare expenditure in developed and developing countries is expected to fuel the growth of the orphan drug market during the forecast period. Moreover, the increasing development of new technologies for orphan drugs is expected to generate a significant opportunity in the future. Stringent regulations in approving new developments in concern towards people's safety remains a significant challenging factor for the market players. Also, the lack of complete knowledge of the manufacturing process with the latest formula is obstructing the growth rate of the market. Continuous changes in government bodies' economic strategies in several countries may also adversely impact the demand for the global orphan drugs market.Orphan Drugs Market Segment Overview:
By Disease Type, Oncology is the dominant market, because of the increasing number of cancer patients, globally. Also, more manufacturing companies like Johnson & Johnson, Abbvie, and Bristol-Myers Squibb are operating in the orphan drugs market related to the oncology segment. The neurology segment is expected to grow at the highest CAGR of xx% in the estimated period with the rise in the incidences of neurological disorders across the globe. Also, growing support from the Food and Drug Administration (FDA) is fueling the orphan drugs market's growth.Orphan Drugs Market Regional Insights:
North America held the largest market share of xx% in 2022. This is mainly because of the increasing prevalence of rare disorders. The high spending on R&D of orphan drugs, coupled with the existence of numerous large-scale local manufacturers will promise well for market growth. The rising demand for the product in the countries from North America such as U.S. and Canada are contributing to the growth of the market in the future. Europe is the second-largest orphan drugs market. This growth is attributed to the many pharmaceutical companies exporting their products outside or within Europe is expected to drive the growth of the market. Also, most of the European companies are focusing on the R&D of orphan drugs according to the patient’s need. Also, several favorable factors such as the introduction of innovative technologies, favorable pricing, reimbursement, unmet medical necessities, and a strong clinical pipeline are contributing to the growth of the orphan drug market during the estimated period. Asia-Pacific is estimated to be the fastest-growing market thanks to the emerging healthcare infrastructure. Due to the increasing occurrence of other diseases such as endocrinology, cardiovascular and lymphatic systems, as well as respiratory disorders, the growth for orphan drugs market is witnessed in Asia-Pacific. Also, the countries in the Asia Pacific such as India and China are contributing the largest shares for the growth of the market. This is mainly on accounts of the launch of reimbursement schemes in favor of ordinary people is also amplifying the demand of the market. The objective of the report is to present a comprehensive analysis of the Market to the stakeholders in the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Market dynamics, structure by analyzing the market segments and project the Global Market size. Clear representation of competitive analysis of key players By Disease Type, price, financial position, product portfolio, growth strategies, and regional presence in the Market make the report investor’s guide.Orphan Drugs Market Scope: Inquire before buying
Global Orphan Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 172.89 Bn. Forecast Period 2022 to 2029 CAGR: 10.83% Market Size in 2029: US $ 355.12 Bn. Segments Covered: by Disease Type Oncology Gastrointestinal Pulmonary Neurology Hematology Cardio-vascular Metabolic disorders Endocrinology Infectious diseases Others by Indication Non-Hodgkin Lymphoma Acute Myeloid Leukemia Cystic Fibrosis Glioma Pancreatic Cancer Ovarian Cancer Multiple Myeloma Duchenne Muscular Dystrophy Graft vs Host Disease Renal Cell Carcinoma Others by Distribution Channel Hospital Pharmacies Specialty Pharmacies Retail pharmacies Others Orphan Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Orphan Drugs Market, Key Players
1. Amgen Inc. 2. Celgene 3. Abbvie 4. Johnson & Johnson 5. Bayer AG 6. F. Hoffmann-La Roche Ltd. 7. Alexion Pharmaceuticals Inc. 8. Novo Nordisk A/S 9. Novartis AG 10. Bristol-Myers Squibb Company 11. AstraZeneca plc. 12. Daiichi Sankyo Company Limited 13. GlaxoSmithKline plc. 14. Vertex Pharmaceuticals 15. Merck & Co., Inc. 16. Boehringer Ingelheim GmbH 17. Biogen Idec 18. Actelion Pharmaceuticals Ltd 19. Janssen Biotech, Inc. 20. Takeda Pharmaceutical Company Limited 21. Eli Lilly and Company 22. Shire Pharmaceutical 23. Sanofi 24. Pfizer Inc.Frequently Asked Questions:
1. Which region has the largest share in Global Orphan Drugs Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Orphan Drugs Market? Ans: The Global Orphan Drugs Market is expected to grow at a CAGR of 10.83% during forecast period 2022-2029. 3. What is scope of the Global Orphan Drugs market report? Ans: Global Orphan Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Orphan Drugs market? Ans: The important key players in the Global Orphan Drugs Market are – , Amgen Inc., Celgene, Abbvie, Johnson & Johnson, Bayer AG, F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., Vertex Pharmaceuticals, Merck & Co., Inc., Boehringer Ingelheim GmbH, Biogen Idec, Actelion Pharmaceuticals Ltd, Janssen Biotech, Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Shire Pharmaceutical, Sanofi, and Pfizer Inc. 5. What is the study period of this market? Ans: The Global Orphan Drugs Market is studied from 2022 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Orphan Drugs Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Orphan Drugs Market 3.4. Geographical Snapshot of the Orphan Drugs Market, By Manufacturer share 4. Global Orphan Drugs Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Orphan Drugs Market 5. Supply Side and Demand Side Indicators 6. Global Orphan Drugs Market Analysis and Forecast, 2022-2029 6.1. Global Orphan Drugs Market Size & Y-o-Y Growth Analysis. 7. Global Orphan Drugs Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 7.1.1. Oncology 7.1.2. Gastrointestinal 7.1.3. Pulmonary 7.1.4. Neurology 7.1.5. Hematology 7.1.6. Cardio-vascular 7.1.7. Metabolic disorders 7.1.8. Endocrinology 7.1.9. Infectious diseases 7.1.10. Others 7.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 7.2.1. Non-Hodgkin Lymphoma 7.2.2. Acute Myeloid Leukemia 7.2.3. Cystic Fibrosis 7.2.4. Glioma 7.2.5. Pancreatic Cancer 7.2.6. Ovarian Cancer 7.2.7. Multiple Myeloma 7.2.8. Duchenne Muscular Dystrophy 7.2.9. Graft vs Host Disease 7.2.10. Renal Cell Carcinoma 7.2.11. Others 7.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 7.3.1. Hospital Pharmacies 7.3.2. Specialty Pharmacies 7.3.3. Retail pharmacies 7.3.4. Others 8. Global Orphan Drugs Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Orphan Drugs Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 9.1.1. Oncology 9.1.2. Gastrointestinal 9.1.3. Pulmonary 9.1.4. Neurology 9.1.5. Hematology 9.1.6. Cardio-vascular 9.1.7. Metabolic disorders 9.1.8. Endocrinology 9.1.9. Infectious diseases 9.1.10. Others 9.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 9.2.1. Non-Hodgkin Lymphoma 9.2.2. Acute Myeloid Leukemia 9.2.3. Cystic Fibrosis 9.2.4. Glioma 9.2.5. Pancreatic Cancer 9.2.6. Ovarian Cancer 9.2.7. Multiple Myeloma 9.2.8. Duchenne Muscular Dystrophy 9.2.9. Graft vs Host Disease 9.2.10. Renal Cell Carcinoma 9.2.11. Others 9.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 9.3.1. Hospital Pharmacies 9.3.2. Specialty Pharmacies 9.3.3. Retail pharmacies 9.3.4. Others 10. North America Orphan Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Orphan Drugs Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 11.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 12. Canada Orphan Drugs Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 12.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 13. Mexico Orphan Drugs Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 13.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 14. Europe Orphan Drugs Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 14.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 15. Europe Orphan Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Orphan Drugs Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 16.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 17. France Orphan Drugs Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 17.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 18. Germany Orphan Drugs Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 18.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 19. Italy Orphan Drugs Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 19.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 20. Spain Orphan Drugs Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 20.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 21. Sweden Orphan Drugs Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 21.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 22. CIS Countries Orphan Drugs Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 22.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 23. Rest of Europe Orphan Drugs Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 23.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 24. Asia Pacific Orphan Drugs Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 24.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 25. Asia Pacific Orphan Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Orphan Drugs Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 26.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 27. India Orphan Drugs Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 27.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 28. Japan Orphan Drugs Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 28.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 29. South Korea Orphan Drugs Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 29.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 30. Australia Orphan Drugs Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 30.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 31. ASEAN Orphan Drugs Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 31.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 32. Rest of Asia Pacific Orphan Drugs Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 32.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 33. Middle East Africa Orphan Drugs Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 33.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 34. Middle East Africa Orphan Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Orphan Drugs Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 35.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 36. GCC Countries Orphan Drugs Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 36.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 37. Egypt Orphan Drugs Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 37.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 38. Nigeria Orphan Drugs Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 38.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 39. Rest of ME&A Orphan Drugs Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 39.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 40. South America Orphan Drugs Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 40.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 41. South America Orphan Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Orphan Drugs Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 42.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 43. Argentina Orphan Drugs Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 43.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 44. Rest of South America Orphan Drugs Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Disease Type, 2022-2029 44.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 44.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Orphan Drugs Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications, and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Amgen Inc. 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Celgene 45.3.3. Abbvie 45.3.4. Johnson & Johnson 45.3.5. Bayer AG 45.3.6. F. Hoffmann-La Roche Ltd. 45.3.7. Alexion Pharmaceuticals Inc. 45.3.8. Novo Nordisk A/S 45.3.9. Novartis AG 45.3.10. Bristol-Myers Squibb Company 45.3.11. AstraZeneca plc. 45.3.12. Daiichi Sankyo Company Limited 45.3.13. GlaxoSmithKline plc. 45.3.14. Vertex Pharmaceuticals 45.3.15. Merck & Co., Inc. 45.3.16. Boehringer Ingelheim GmbH 45.3.17. Biogen Idec 45.3.18. Actelion Pharmaceuticals Ltd 45.3.19. Janssen Biotech, Inc. 45.3.20. Takeda Pharmaceutical Company Limited 45.3.21. Eli Lilly and Company 45.3.22. Shire Pharmaceutical 45.3.23. Sanofi 45.3.24. Pfizer Inc. 46. Primary Key Insights